This is largely a promo for Unity Biotechnology and the associated labs. It fails to mention, e.g. SIWA Therapeutics and their work on antibodies, Oisin Biotechnologies and their gene therapy DNA constructs for destroying cells based on internal chemistry, the company that David Sinclair is starting for senolytics, that Betterhumans has beaten Unity to the punch and is currently running phase 0 human pilots of dasatinib and quercetin on a non-profit basis. Also that senescent cell clearance didn't magically spring into being in 2011, but appears clearly in Aubrey de Grey's position paper on human rejuvenation in 2002, and the Methuselah Foundation, SENS Research Foundation, and others have been advocating hard for more work in this direction in the face of a research community that rejected it for a decade.

But hey, if you beat the competitors to be the first to raise 9-figure sums of venture capital, then you too can engineer attention to shine on you only, and rewrite history more or less as you like for a while.

So far all ways to address aging in mice have slowed aging by tinkering with metabolism, but slowing down the damage accumulation. They all produce much larger effects in short-lived species, probably because long-lived species have evolved to have many of these metabolic items turned on already. Calorie restriction extends life by 40% in mice, and I can assure you that while it is pretty beneficial in humans, you are not going to add more than a couple of extra years. Senescent cell clearance is the first way to address aging that involves repair of damage rather than slowing it down: we have no idea how the size of benefit in mice will translate to humans. So 25% gains in mice can be exciting here, whereas for any slowing-aging-only approach it would be a yawn.